Literature DB >> 25582282

Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A.

S Kepa1, B Horvath2, S Reitter-Pfoertner1, M Schemper3, P Quehenberger2, M Grundbichler4, M Heistinger5, P Neumeister6, C Mannhalter2, I Pabinger1.   

Abstract

In haemophilia A patients factor VIII (FVIII) recovery and half-life can vary substantially. There are parameters known to modulate FVIII pharmacokinetics (PK), but they explain only about 34% of the variability. The aim of this study was to identify new parameters that influence FVIII PK and thus to expand the current knowledge. FVIII PK were determined in 42 haemophilia A patients (37 severe, 5 moderate) without inhibitor. Patients' characteristics and laboratory parameters were evaluated for an association with FVIII PK. We analysed plasma levels of low-density lipoprotein receptor-related protein 1 (LRP1) and protein C (PC) activity, which had been hypothesized to influence FVIII activity. Furthermore, four variations in intron 6 of the LRP1 gene, which had been shown to influence LRP1, were investigated. FVIII half-life differed widely from 6.2 to 20.7 h, with a median of 10.0 h. Patients with blood group O had shorter FVIII half-life compared to patients with non-O blood group (median FVIII half-life 9.0 h vs. 10.4 h, P = 0.018). Age was significantly associated with FVIII half-life (r = 0.32, P = 0.035). Besides age, also VWF antigen (r = 0.52, P < 0.001) and blood group (r = -0.37, P = 0.015) was associated with FVIII half-life. No correlation was found with FVIII- or LRP1-genotype, LRP1 or PC concentrations. Our data showed large differences in FVIII PK between individual patients and revealed age, blood group and VWF levels as important determining factors for FVIII half-life. FVIII genotype or levels of LRP1 or PC had no influence on FVIII PK.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  Haemophilia A; LRP1; LRP1 polymorphisms; Protein C; influences on FVIII pharmacokinetics

Mesh:

Substances:

Year:  2015        PMID: 25582282     DOI: 10.1111/hae.12592

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  16 in total

1.  Applicability of the Thrombin Generation Test to Evaluate the Hemostatic Status of Hemophilia A Patients in Daily Clinical Practice.

Authors:  Ángel Bernardo; Alberto Caro; Daniel Martínez-Carballeira; José Ramón Corte; Sonia Vázquez; Carmen Palomo-Antequera; Alfredo Andreu; Álvaro Fernández-Pardo; Julia Oto; Laura Gutiérrez; Inmaculada Soto; Pilar Medina
Journal:  J Clin Med       Date:  2022-06-10       Impact factor: 4.964

2.  Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A.

Authors:  Zhenping Chen; Kun Huang; Gang Li; Yingzi Zhen; Xinyi Wu; Ai Di; Guoqing Liu; Zekun Li; Iorio Alfonso; Runhui Wu
Journal:  Pediatr Investig       Date:  2021-03-22

3.  Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.

Authors:  Johnny Mahlangu; Kazimierz Kuliczkowski; Faraizah Abdul Karim; Oleksandra Stasyshyn; Marina V Kosinova; Lynda Mae Lepatan; Aleksander Skotnicki; Lisa N Boggio; Robert Klamroth; Johannes Oldenburg; Andrzej Hellmann; Elena Santagostino; Ross I Baker; Kathelijn Fischer; Joan C Gill; Stephanie P'Ng; Pratima Chowdary; Miguel A Escobar; Claudia Djambas Khayat; Luminita Rusen; Debra Bensen-Kennedy; Nicole Blackman; Tharin Limsakun; Alex Veldman; Katie St Ledger; Ingrid Pabinger
Journal:  Blood       Date:  2016-06-21       Impact factor: 22.113

Review 4.  Genetic regulation of plasma von Willebrand factor levels in health and disease.

Authors:  L L Swystun; D Lillicrap
Journal:  J Thromb Haemost       Date:  2018-10-30       Impact factor: 5.824

5.  Mechanistic Insights into Factor VIII Immune Tolerance Induction via Prenatal Cell Therapy in Hemophilia A.

Authors:  Martin Rodriguez; Christopher D Porada; Graҫa Almeida-Porada
Journal:  Curr Stem Cell Rep       Date:  2019-11-20

6.  Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study.

Authors:  Zhen-Ping Chen; Pei-Jing Li; Gang Li; Ling Tang; Ying-Zi Zhen; Xin-Yi Wu; Xiao-Ling Cheng; Koon Hung Luke; Victor S Blanchette; Man-Chiu Poon; Qiu-Lan Ding; Run-Hui Wu
Journal:  Chin Med J (Engl)       Date:  2018-08-05       Impact factor: 2.628

7.  Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non-severe haemophilia A.

Authors:  Judit Rejtő; Oliver Königsbrügge; Ella Grilz; Stefanie Hofer; Lisa-Marie Mauracher; Cornelia Gabler; Gerhard Schuster; Clemens Feistritzer; Raute Sunder-Plaßmann; Peter Quehenberger; Johanna Gebhart; Cihan Ay; Ingrid Pabinger
Journal:  J Thromb Haemost       Date:  2020-03-20       Impact factor: 5.824

8.  Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial.

Authors:  Renchi Yang; Jing Sun; Yongqiang Zhao; Xuefeng Wang; Depei Wu; Despina Tseneklidou-Stoeter; Junde Wu; Nikki Church
Journal:  Haemophilia       Date:  2019-04-17       Impact factor: 4.287

Review 9.  Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia.

Authors:  Peter L Turecek; Jill M Johnsen; Steven W Pipe; James S O'Donnell
Journal:  Haemophilia       Date:  2020-06-28       Impact factor: 4.287

Review 10.  Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia.

Authors:  Tim Preijers; Lisette M Schütte; Marieke J H A Kruip; Marjon H Cnossen; Frank W G Leebeek; Reinier M van Hest; Ron A A Mathôt
Journal:  Clin Pharmacokinet       Date:  2021-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.